Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can doctors match the right arthritis drug to the right child?

NCT ID NCT07814963

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers at Sohag University are following 50 children under 18 who have systemic juvenile idiopathic arthritis, a rare inflammatory disease that affects the whole body. The study records each child's symptoms, lab results, complications, and the treatments they receive, including the drug tocilizumab. By tracking disease activity over time, the team aims to understand how the condition behaves and how children respond to different treatment approaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tocilizumab, a drug used in routine care for systemic juvenile idiopathic arthritis
What this could lead to
If the study succeeds, it could give doctors a clearer picture of which children with systemic juvenile idiopathic arthritis respond best to which treatments, including tocilizumab.
What could go wrong
This is a small observational study at one center, so its findings may not apply to all children with this rare disease. It does not test a new treatment and cannot prove that one therapy works better than another.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of children younger than 18 years of age diagnosed with systemic juvenile idiopathic arthritis (sJIA) according to the 2019 PRINTO classification criteria. Participants will be recruited from the pediatric rheumatology service and followed prospectively to assess their clinical course, disease activity, response to treatment, treatment-related outcomes, and disease complications.

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged \<18 years. * Children diagnosed with systemic juvenile idiopathic arthritis (sJIA) according to the 2019 PRINTO classification criteria. * Both newly diagnosed and previously diagnosed children with sJIA attending the study center. Exclusion Criteria: * Children with other rheumatic or autoimmune diseases. * Children with infectious, malignant, or other systemic diseases that may mimic sJIA. * Patients whose medical records have insufficient data for assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic juvenile idiopathic arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis systemic-onset juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic juvenile idiopathic arthritis Systemic juvenile idiopathic arthritis (SJIA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sohag university hospital

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.